Subscribe for free to our flagship newsletter, CDR: This Week in Retail, for news and insights from the voice of retail pharmacy.

Skip to content

Dr. Reddy’s ships generic version of Exelon

Dr. Reddy’s Laboratories has launched rivastigmine tartrate capsules, a treatment for dementia caused by Alzheimer’s or Parkinson’s disease, in the U.S. market. The pharmaceutical company said Thursday that its rivastigmine tartrate capsules are available in strengths of 1.5 mg, 3 mg, 4.

HYDERABAD, India — Dr. Reddy’s Laboratories has launched rivastigmine tartrate capsules, a treatment for dementia caused by Alzheimer’s or Parkinson’s disease, in the U.S. market.

The pharmaceutical company said Thursday that its rivastigmine tartrate capsules are available in strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg and come in 60-count bottles.

According to Dr. Reddy’s, the Food and Drug Administration-approved product is a bioequivalent generic version of Novartis’ Exelon capsules.

U.S. sales of Exelon brand and generic rivastigmine tartrate capsules totaled approximately $92.6 million for the 12 months ended June 2011, according to IMS Health data cited by Dr. Reddy’s.

Comments

Latest